

令和4年度 研究成果の刊行に関する一覧表

【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
長谷川稔	硬化性苔癬	高橋健造 佐伯秀久	皮膚疾患 最新の治療 2023-2024	㈱南江堂	日本	2023	111
浅野善英	【これ1冊！皮膚科領域における膠原病診療の極意】強皮症の診断と治療の極意	茂木精一郎	Derma	全日本病院出版会	日本	2022	1-10
大竹里奈、沖山奈緒子	限局性強皮症の診断と治療の極意	茂木精一郎	MB Derma No. 326	全日本病院出版会	日本	2022	19-25
川口鎮司	多発性筋炎、皮膚筋炎	門脇 孝 小室一成 宮地良樹	治療ガイドライン UP-TO-DATE 2022- 2023	メディカルレビュー社	日本	2022	659-665
長谷川稔	リウマチ性疾患の皮膚病変のみかた	日本リウマチ財団教育 研修委員会 日本リウマチ学会生涯 教育委員会	リウマチ病学 テキスト	㈱南江堂	日本	2022	68-75
長谷川稔	レイノー現象をきたす疾患	常深祐一郎 渡辺大輔	皮膚疾患診療第3版 実践ガイド	㈱文光堂	日本	2022	35-36
長谷川稔	全身性強皮症	常深祐一郎 渡辺大輔	皮膚疾患診療第3版 実践ガイド	㈱文光堂	日本	2022	405-408
長谷川稔	限局性強皮症	常深祐一郎 渡辺大輔	皮膚疾患診療第3版 実践ガイド	㈱文光堂	日本	2022	408-409
尾山徳孝、長谷川稔	硬化性苔癬	常深祐一郎 渡辺大輔	皮膚疾患診療第3版 実践ガイド	㈱文光堂	日本	2022	775-777
茂木精一郎	これ1冊！皮膚科領域における膠原病診療の極意	茂木精一郎	Dermaこれ1冊！皮膚科領域における 膠原病診療の極意	全日本病院出版会	日本	2022	1
茂木精一郎	ステロイド投与の対象となる強皮症は？	宮地良樹 常深祐一郎	皮膚科診療 Controversy	中外医学社	日本	2022	181-184
茂木精一郎	強皮症	神人正寿 常深祐一郎	皮膚科診療秘伝の書	南江堂	日本	2022	72-79

【雑誌】

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kubota N, Tanaka R, Ichimura Y, Konishi R, Tso JY, Tsurushita N, Nomura T, Okiyama N	Blockade of CD122 on memory T cells in the skin suppresses sclerodermatous graft-versus-host disease.	J Dermatol Sci.	Online		2023
<u>Kuwana M</u> , Bando M, Kawahito Y, Sato S, Suda T, and Kondoh Y	Identification and management of connective tissue disease-associated interstitial lung disease: evidence-based Japanese consensus statements	Expert Rev Respir Med	doi: 10.1080/17476348. 2023.2176303	Online ahead of print	2023
<u>Kuwana M</u> , Abe K, Kinoshita K, Matsubara H, Minatsuki S, Murohara T, Sakao S, Shirai Y, Tahara N, Tsujino I, Takahashi K, Kanda S, and Ogo T	Efficacy, safety and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension	Pulm Circ	13	e12198	2023
Khanna D, Maher TM, Volkmann ER, Allanore Y, Smith V, Assassi S, Kreuter M, Hoffmann-Vold AM, <u>Kuwana M</u> , Stock C, Alves M, Sambevski S, Denton CP on behalf of the SENSICIS trial investigators	Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression	RMD Open	9	e00285	2023
Nagahata K, Suzuki C, Takahashi H.	Spurious macrocytic anemia in a patient with systemic lupus erythematosus: cold agglutinin disease.	Clin Rheumatol	doi: 10.1007/s10067- 023-06536-5		2023
Ishikawa M, Endo Y, Yamazaki S, Sekiguchi A, Uchiyama A, Motegi SI.	Real-world effectiveness and safety of bosentan in Japanese patients with systemic sclerosis: A single-center retrospective study.	Journal of Dermatology	in press		2023

Wang W, Bale S, Wei J, Yalavarthi B, Bhattacharyya D, Yan JJ, Abdala-Valencia H, Xu D, Sun H, Marangoni RG, Herzog E, Berdnikovs S, Miller SD, Sawalha AH, Tsou PS, Awaji K, Yamashita T, Sato S, Asano Y, Tiruppathi C, Yeldandi A, Schock BC, Bhattacharyya S, Varga J	Fibroblast A20 governs fibrosis susceptibility and its repression by DREAM promotes fibrosis in multiple organs.	Nat Commun.	13(1)	6358	2022
Ikawa T, Ichimura Y, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y	The Contribution of LIGHT (TNFSF14) to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts.	J Invest Dermatol.	142(6)	1541-1551	2022
Yamamoto A, Saito T, Hosoya T, Kawahata K, Asano Y, Sato S, Mizoguchi F, Yasuda S, Kohsaka H	Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis.	Arthritis Rheumatol.	74(5)	860-870	2022
Ichimura Y, Ikei H, Konishi R, Zeniya M, Okai T, Nomura T, Negishi K, Okiyama N	Relevance of leukemia inhibitory factor to anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease.	Rheumatology (Oxford)	Online		2022
Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng RX, Otomo N, Kwon YC, Sheng Y, Sugano N, Hwang MY, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung WT, Huang H, Takahashi D, Lee SS, Wang M, Karino K, Shim SC, Zheng X, Miyamura T, Kang YM, Ye D, Nakamura J, Suh CH, Tang Y, Motomura G, Park YB, Ding H, Kuroda T, Choe JY, Li C, Niuro H, Park Y, Shen C, Miyamoto T, Ahn GY, Fei W, Takeuchi T, Shin JM, Li K, Kawaguchi Y, Lee YK, Wang YF, Amano K, Park DJ, Yang W, Tada Y, Lau YL, Yamaji K, Zhu Z, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y	Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study.	Ann Rheum Dis	81	1273-1280	2022
Kimura N, Kawahara T, Uemura Y, Atsumi T, Sumida T, Mimura T, Kawaguchi Y, Amano H, Iwasaki Y, Kaneko Y, Matsui T, Muro Y, Imura Y, Kanda T, Tanaka Y, Kawakami A, Jinnin M, Ishii T, Hiromura K, Miwa Y, Nakajima H, Kuwana M, Nishioka Y, Morinobu A, Kameda H, Kohsaka H	Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multicenter, randomized controlled trial	Rheumatology	61	4445-4454	2022
Watanabe A, Shima Y, Takahashi H, Akiyama Y, Koderia M, Jinnin M, Azuma N, Ishii K, Kumanogoh A	Arm heating to relieve Raynaud's phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial.	Modern Rheumatology	roac116	1-7	2022
Bruni C, Buch MH, Djokovic A, De Luca G, Dumitru RB, Giollo A, Galetti I, Steelandt A, Bratis K, Suliman YA, Milinkovic I, Baritussio A, Hasan G, Xintarakou A, Isomura Y, Markousis-Mavrogenis G, Mavrogeni S, Gargani L, Caforio ALP, Tschöpe C, Ristic A, Plein S, Behr E, Allanore Y, Kuwana M, Denton CP, Furst DE, Khann D, Krieg T, Marcolongo R, Pope A, Distler O, Seferovic P, and Matucci-Cerinic M	Consensus on the assessment of Systemic Sclerosis-associated primary Heart Involvement: WSF/HFA guidance on screening, diagnosis, and follow-up assessment	J. Scleroderma Relat. Disord	In press		
Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, and Khanna D	Therapeutic approaches to systemic sclerosis: Recent approvals and future candidate therapies	Clin. Rev. Allergy Immunol	doi: 10.1007/s12016-021-08891-0	Online ahead of print	
Hughes M, Allanore Y, Baron M, del Galdo F, Denton CP, Frech T, Furst D, Galetti I, Dagna L, Herrick A, Kuwana M, Matucci-Cerinic P, McMahan Z, Murray C, Proudman S, and Matucci-Cerinic M	Proton pump inhibitors in systemic sclerosis, a reappraisal to optimise the fight against reflux	Lancet Rheumatol	4(11)	e795-e803	2022

Kuster S, Jordan S, Elhai M, Held U, Steigmiller K, Bruni C, Cacciapaglia F, Vettori S, Siegert E, Rednic S, Codullo V, Airo P, Braun-Moscovici Y, Hunzelmann N, Joao Salvador M, Riccieri V, Gheorghiu AM, Alegre Sancho JJ, Romanowska-Prochnicka K, Castellvi I, Kötter I, Truchetet ME, López-Longo FJ, Novikov PI, Giollo A, Shirai Y, Belloli L, Zanatta E, Hachulla E, Smith V, Denton C, Ionescu RM, Schmeiser T, Distler JHW, Gabrielli A, Hoffmann-Vold AM, <u>Kuwana M</u> , Allanore Y, Distler O, and EUSTAR collaborators	Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort	RMD Open	8(2)	e002477	2022
Isomura Y, Shirai Y, and <u>Kuwana M</u>	Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan	Rheumatology (Oxford)	61(11)	4491-4496	2022
Kakkar V, Assassi S, Allanore Y, <u>Kuwana M</u> , Denton C, Khanna D, and Del Galdo F	Type 1 interferon activation in SSc: a biomarker, a target or the culprit?	Opinion Rheumatol	34(6)	357-364	2022
Yomono K and <u>Kuwana M</u>	Outcomes in patients with systemic sclerosis undergoing early vs delayed intervention with potential disease-modifying therapies	Rheumatology (Oxford)	61(9)	3677-3685	2022
<u>Kuwana M</u> , Saito A, Sakamoto W, Raabe C, and Saito K	Incidence rate and prevalence of systemic sclerosis and systemic-sclerosis-associated interstitial lung disease in Japan: analysis using Japanese claims databases	Adv. Ther	39(5)	2222-2235	2022
Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, Denton CP, Luppi F, Ruaro B, Della Casa F, De Luca G, Spinicci M, Zammarchi L, Tomassetti S, Caminati A, Cavigli E, Albanesi M, Melchiorre F, Palmucci S, Vegni V, Guiducci S, Moggi-Pignone A, Allanore Y, Bartoloni A, Confalonieri M, Cortese G, Dagna L, de Cobelli F, de Paulis A, Harari S, Khanna D, <u>Kuwana M</u> , Taliani G, Lavorini F, Miele V, Morana G, Pesci A, Vancheri C, Colagrande S, and Matucci-Cerinic M	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19	Rheumatology (Oxford)	61(4)	1600-1609	2022
<u>Kuwana M</u> , Allanore Y, Denton CP, Distler JHW, Steen VD, Khanna D, Matucci-Cerinic M, Mayes MD, Volkman ER, Miede C, Gahlemann M, Quaresma Lic M, Alves M, and Distler O	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score	Arthritis Rheumatol	74(3)	518-526	2022
Shirai Y, Kawami N, Iwakiri K, and <u>Kuwana M</u>	Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis	J. Scleroderma Relat. Disord	7(1)	57-61	2022
Bruni C, Buch MH, De Luca G, Djokovic A, Dumitru RB, Giollo A, Polovina M, Steelandt A, Bratis K, Suliman YA, Milinkovic I, Baritussio A, Hasan G, Xintarakou A, Isomura Y, Markousis-Mavrogenis G, Tofani L, Mavrogeni S, Gargani L, Caforio ALP, Tschoepe C, Ristic A, Klingel K, Plein S, Behr E, Allanore Y, <u>Kuwana M</u> , Denton CP, Furst DE, Khann D, Krieg T, Marcolongo R, Galetti I, Seferovic P, and Matucci-Cerinic M	Primary systemic sclerosis heart involvement: a systematic literature review and preliminary consensus-based WSF/HFA definition	J. Scleroderma Relat. Disord	7(1)	24-32	2022
Sawamura S, Makino K, Ide M, Shimada S, Kajihara I, Makino T, Jinnin M, Fukushima S.	Elevated Alpha 1(I) to Alpha 2(I) Collagen Ratio in Dermal Fibroblasts Possibly Contributes to Fibrosis in Systemic Sclerosis.	Int J Mol Sci.	23(12)	6811	2022
Tabata K, Kaminaka C, Yasutake M, Matsumiya R, Inaba Y, Yamamoto Y, Jinnin M, Fujii T.	Forearm porphyrin levels evaluated by digital imaging system are increased in patients with systemic sclerosis compared with patients in pre-clinical stage.	Intractable Rare Dis Res.	11(1)	1-6	2022
Murayama K, Ikegami I, Kamekura R, Sakamoto H, Yanagi M, Kamiya S, Sato T, Sato A, Shigehara K, Yamamoto M, Takahashi H, Takano KI, Ichimiya S.	CD4+CD8+ T follicular helper cells regulate humoral immunity in chronic inflammatory lesions.	Front Immunol	doi: 10.3389/fimmu.2022.941385.		2022
Utsunomiya A, Chino T, Kasamatsu H, Hasegawa T, Utsunomiya N, Luong VH, Matsushita T, Sasaki Y, Ogura D, Niwa SI, Oyama N, Hasegawa M.	The compound LG283 inhibits bleomycin-induced skin fibrosis via antagonizing TGF-β signaling.	Arthritis Res Ther.	24(1)	94	2022

Oyama N, Hasegawa M.	Lichen Sclerosus: A Current Landscape of Autoimmune and Genetic Interplay.	Diagnos-tics (Basel).	12(12)	3070	2022
Sawamura S, Makino K, Ide M, Shimada S, Kajihara I, Makino T, Jinnin M, Fukushima S.	Elevated Alpha 1(I) to Alpha 2(I) Collagen Ratio in Dermal Fibroblasts Possibly Contributes to Fibrosis in Systemic Sclerosis.	Int J Mol Sci.	23(12)	6811	2022
Endo Y, Kim J, Uchiyama A, Yasuda M, Hara K, Motegi SI	Spontaneous pneumomediastinum developed after steroid pulse therapy in diffuse cutaneous systemic sclerosis patient: A case report.	Journal of Dermatology	49(6)	e185-e186	2022
Saito S, Endo Y, Nishio M, Uchiyama A, Uehara A, Toki S, Yasuda M, Ishikawa O, Muro Y, Motegi SI.	Anti-polymyositis/Scl antibody-positive overlap syndrome of diffuse cutaneous systemic sclerosis, dermatomyositis, systemic lupus erythematosus, and antiphospholipid syndrome.	Journal of Dermatology	49(2)	294-298	2022
長谷川稔	全身性強皮症におけるB細胞とマクロファージの役割	RHEUMATOLOGYリウマチ科	69(1)	106-112	2023
嶋 良仁	抗interleukin-6受容体抗体トシリズマブによる治療	皮膚科	Vol.1(5)	658-664	2022
長谷川稔	血管変化を鋭敏に検出するキャピラスコピーの活用-膠原病診療において-	DERMATOLOGY 皮膚科	1(4)	517-524	2022
牧野雄成	【Geneticsとepigenetics】全身強皮症(解説)	皮膚科	2(6)	719-727	2022
牧野雄成、當眞嗣雅、立石 大、藤田美歌子、大塚雅巳、片岡良友	全身性強皮症の分子病態と治療薬創製(解説)	Bio Clinica.	37(9)	844-849	2022
牧野 雄成	特殊な全身性強皮症(generalized morphealike SSc、薬剤性、職業性)(解説)	皮膚科	1(5)	681-685	2022
牧野貴充、牧野雄成	【全身性強皮症-最新の話題-】臨床 レイノー現象、指尖潰瘍、毛細血管異常、石灰沈着(解説)	皮膚科	1(5)	612-617	2022
茂木精一郎	全身性強皮症	皮膚科の臨床	64(7)	1211-1225	2022
茂木精一郎	膠原病の顔の皮疹とその鑑別	皮膚科	1(1)	136-142	2022
茂木精一郎	全身性強皮症 最近の話題 血管障害の治療	皮膚科	1(5)	639-646	2022

令和3年度 研究成果の刊行に関する一覧表

【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
川口鎮司、樋口智昭	特に強皮症に伴う肺動脈性肺高血圧症	長谷川好規	日本臨床	日本臨床社	日本	2021	254-259
長谷川 稔	膠原病を疑う皮膚症状	藤本 学	皮膚科ベストセレクション 皮膚科 膠原病 皮疹から全身を診る	中山書店	日本	2021	2-6
内田沙織, 尾山徳孝	Atrophoderma of Pasini and Pierini (Pasini-Pierini型進行性特発性皮膚萎縮症)	藤本 学	皮膚科ベストセレクション 皮膚科 膠原病 皮疹から全身を診る	中山書店	日本	2021	236-238
長谷川 稔	硬化性苔癬	藤本 学	皮膚科ベストセレクション 皮膚科 膠原病 皮疹から全身を診る	中山書店	日本	2021	249-251
長谷川 稔	限局性強皮症	福井次矢 高木 誠 小室一成	今日の治療指針 私はこう治療している2022年版	医学書院	日本	2021	1299-1300
長谷川 稔	自己抗体の読み方	佐藤伸一 藤本 学 門野岳史 梶島健治	今日の皮膚疾患治療指針 第5版 Today's Therapy in Dermatology	医学書院	日本	2022	177-179
長谷川 稔	ステロイド薬	佐藤伸一 藤本 学 門野岳史 梶島健治	今日の皮膚疾患治療指針 第5版 Today's Therapy in Dermatology	医学書院	日本	2022	252-254
長谷川 稔	膠原病 最近の動向	佐藤伸一 藤本 学 門野岳史 梶島健治	今日の皮膚疾患治療指針 第5版 Today's Therapy in Dermatology	医学書院	日本	2022	483-485
長谷川 稔	硬化性苔癬	佐藤伸一 藤本 学 門野岳史 梶島健治	今日の皮膚疾患治療指針 第5版 Today's Therapy in Dermatology	医学書院	日本	2022	1041-1042
波多野 将	肺高血圧症の診断と治療	藤本 学	皮膚科 膠原病 皮疹から全身を診る	中山書店	日本	2021	186-190
牧野雄成・大塚雅巳	全身性強皮症治療薬の開発研究	神戸直智・ 梶島健治	皮膚疾患と慢性炎症	北隆館	日本	2021年	122-127
茂木精一郎	指がこわばる	宮地良樹	愁訴から考える皮膚疾患診断ベストプラクティス	メディカルレビュー社	日本	2021	pp. 139-143
茂木精一郎	強皮症	梶島健治、 宮地良樹	エビデンスに基づく皮膚科新薬の治療指針	中山書店	日本	2021	pp. 254-261
茂木精一郎	限局性強皮症	福井次矢、 高木 誠、 小室一成	今日の治療指針 私はこう治療している	医学書院	日本	2021	

【雑誌】

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Nhung Thi My Ly, Ikuko Ueda-Hayakawa, Chuyen Thi Hong Nguyen, Trang Nguyen Mai Huynh, Izumi Kishimoto, Manabu Fujimoto, Hiroyuki Okamoto	Imbalance toward TFH 1 cells playing a role in aberrant B cell differentiation in systemic sclerosis	Oxford Academic	60(3)	1553-1562	2021
Ingrid E Lundberg, Manabu Fujimoto, Jiri Vencovsky, Rohit Aggarwal, Marine Holmqvist, Lisa Christopher-Stine, Andrew L Mammen, Frederick W Miller	Idiopathic inflammatory myopathies	Nature Reviews Disease Primers	7(1)	86	2021
Naoko Okiyama, Yuki Ichimura, Miwako Shobo, Ryota Tanaka, Noriko Kubota, Akimasa Saito, Yosuke Ishitsuka, Rei Watanabe, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Akihiro Murakami, Hisako Kayama, Kiyoshi Takeda, Manabu Fujimoto	Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1 γ can result in experimental myositis	Annals of the Rheumatic Diseases	80(9)	1201-1208	2021
Akimasa Saito, Yuki Ichimura, Noriko Kubota, Ryota Tanaka, Yoshiyuki Nakamura, Yasuhiro Fujisawa, Rei Watanabe, Yosuke Ishitsuka, Manabu Fujimoto, Naoko Okiyama	IFN- γ -Stimulated Apoptotic Keratinocytes Promote Sclerodermatous Changes in Chronic Graft-Versus-Host Disease	Journal of Investigative Dermatology	141(6)	1473-1481	2021

Noriko Arase, Hideaki Tsuji, Hyota Takamatsu, Hui Jin, Hachiro Konaka, Yasuhito Hamaguchi, Kyoko Tonomura, Yori-hisa Kotobuki, Ikuko Ueda-Hayakawa, Sumiko Matsuoaka, Toru Hirano, Hideki Yorifuji, Hiroyuki Murota, Koichiro Ohmura, Ran Nakashima, Tomoharu Sato, Atsushi Kumanogoh, Ichiro Katayama, Hisashi Arase, Manabu Fujimoto	Cell surface-expressed Ro52/IgG/HLA-DR complex is targeted by autoantibodies in patients with inflammatory myopathies	Journal of Autoimmunity	126		2022
Utsunomiya A, Hasegawa M, Oyama N, Asano Y, Endo H, Fujimoto M, Goto D, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara K, Ihn H.	Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.	Mod Rheumatol.	31(1)	162-170	2021
Omatsu J, Saigusa R, Miyagawa T, Fukui Y, Toyama S, Awaji K, Ikawa T, Norimatsu Y, Yoshizaki A, Sato S, Asano Y.	Serum S100A12 levels: possible association with skin sclerosis and interstitial lung disease in systemic sclerosis.	Exp Dermatol.	30(3)	409-415	2021
Ikawa T, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis.	Int J Rheum Dis.	24(2)	260-267	2021
Kotani H, Yoshizaki A, Matsuda KM, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum calponin 3 levels in patients with systemic sclerosis: possible association with skin sclerosis and arthralgia.	J Clin Med.	10(2)	280	2021
Kuzumi A, Yoshizaki A, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum TARC levels in patients with systemic sclerosis: clinical association with interstitial lung disease.	J Clin Med.	10(4)	660	2021
Matsuda KM, Yoshizaki A, Kotani H, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Clinical significance of anti-U1 ribonucleoprotein antibody in anti-topoisomerase I antibody-positive systemic sclerosis patients: a retrospective observational study.	Arch Clin Biomed Res.	5(1)	76-84	2021
Matsuda KM, Yoshizaki A, Kotani H, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum heat shock protein 27 levels in patients with systemic sclerosis: a possible biomarker of skin sclerosis.	J Eur Acad Dermatol Venereol.	35(2)	e157-e159	2021
Yuki F, Nakamura K, Hirabayashi M, Miyagawa T, Toyama S, Omatsu J, Awaji K, Ikawa T, Norimatsu Y, Yoshizaki A, Sato S, Asano Y.	Serum vasohibin-1 levels: a potential marker of dermal and pulmonary fibrosis in systemic sclerosis.	Exp Dermatol.	30(7)	951-958	2021
Awaji K, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Norimatsu Y, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	A potential contribution of decreased serum galectin-10 levels to systemic inflammation and pulmonary vascular involvement in systemic sclerosis.	Exp Dermatol.	30(7)	959-965	2021
Ikawa T, Miyagawa T, Fukui Y, Minatsuki S, Maki H, Inaba T, Hatano M, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis.	Int J Rheum Dis.	24(5)	711-718	2021
Saigusa R, Toyama T, Ichimura Y, Taniguchi T, Yoshizaki A, Sato S, Asano Y.	A case of systemic sclerosis complicated with portal hypertension.	J Clin Rheumatol.	27(8S)	S668-S669	2021
Norimatsu Y, Miyagawa T, Fukui Y, Omatsu J, Toyama S, Awaji K, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Serum levels of tissue factor pathway inhibitor: potential association with Raynaud's phenomenon and telangiectasia in patients with systemic sclerosis.	J Dermatol.	48(8)	1253-1256	2021
Ebata S, Yoshizaki A, Oba K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Asano Y, Okiyama N, Kodera M, Hasegawa M, Sato S.	Safety and efficacy of rituximab in systemic sclerosis: a double-blind, parallel-group comparison, investigators initiated clinical trial (DESIREs).	Lancet Rheumatol.	in press		
Norimatsu Y, Yoshizaki A, Kabeya Y, Fukasawa T, Omatsu J, Fukayama M, Kuzumi A, Ebata S, Yoshizaki-Ogawa A, Asano Y, Ichimura H, Yonezawa S, Nakano H, Sato S.	Expert-Level Distinction of Systemic Sclerosis from Hand Photographs Using Deep Convolutional Neural Networks.	J Invest Dermatol.	141(10)	2536-2539	2021
Numajiri H, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Kazoe Y, Mawatari K, Kitamori T, Yoshizaki A, Sato S.	B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis.	Arthritis Rheumatol.	73(11)	2086-2095	2021
Miura S, Watanabe Y, Saigusa R, Yamashita T, Nakamura K, Hirabayashi M, Miyagawa T, Yoshizaki A, Trojanowska M, Sato S, Asano Y.	Fli1 deficiency suppresses RALDH1 activity of dermal dendritic cells and related induction of regulatory T cells: a possible role in scleroderma.	Arthritis Res Ther.	23(1)	137	2021
Kuzumi A, Yoshizaki A, Matsuda KM, Kotani H, Norimatsu Y, Fukayama M, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Morikawa K, Kazoe Y, Mawatari K, Kitamori T, Sato S.	Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis.	Nat Commun.	12(1)	5974	2021
Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S.	Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease.	J Dermatol.	49(1)	179-183	2022

Ikawa T, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Endothelial CCR6 expression due to FLII1 deficiency contributes to vasculopathy associated with systemic sclerosis.	Arthritis Res Ther.	23(1)	283	2021
Ikawa T, Ichimura Y, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	The Contribution of LIGHT to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts.	J Invest Dermatol.	doi: 10.1016/j.jid.2021.10.028.		2021
Fukasawa T, Yoshizaki A, Ebata S, Yoshizaki-Ogawa A, Asano Y, Enomoto A, Miyagawa K, Kazoe Y, Mawatari K, Kitamori T, Sato S.	Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model.	Elife.	10	e67209	2021
Yamamoto A, Saito T, Hosoya T, Kawahata K, Asano Y, Sato S, Mizoguchi F, Yasuda S, Kohsaka H.	Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis.	Arthritis Rheumatol.	74(5) doi: 10.1002/art.42042.	860-870	2021
Ebata S, Yoshizaki A, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S.	Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study.	Diagnosic s (Basel).	11	2274	2021
Ebata S, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Asano Y, Yoshizaki A, Sato S.	Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: a machine learning analysis of the DESIRES trial	Rheumatology (Oxford).	doi: 10.1093/rheumatology/keac023.		2022
Okiyama N, Iwasaki R, Fukuzono M, Endo R, Inoue S, Ichimura Y, Sato K, Tajiri K, Ieda M, Nomura T.	Successful treatment of pulmonary hypertension with immunosuppressive therapy in a case of anti-synthetase syndrome.	J Dermatol.	48	e545-e546	2021
Fukuzono M, Sasaki K, Ichimura Y, Inoue S, Iwasaki R, Imai H, Saito A, Kubota N, Tanaka R, Nakamura Y, Fujisawa Y, Fujimoto M, Nomura T, Okiyama N.	A case of anti-PL-7 antibody-positive anti-synthetase syndrome with dermatomyositis-associated erythema induced sclerodermatous changes.	Rheumatology (Oxford).	60	e362-e364	2021
Saito A, Ichimura Y, Kubota N, Tanaka R, Nakamura Y, Fujisawa Y, Watanabe R, Ishitsuka Y, Fujimoto M, Okiyama N.	IFN- γ -Stimulated Apoptotic Keratinocytes Promote Sclerodermatous Changes in Chronic Graft-Versus-Host Disease.	J Invest Dermatol.	141	1473-1481	2021
Shimizu T, Saito C, Watanabe M, Ishii R, Kawamura T, Nagai K, Fujita A, Kaneko S, Kai H, Morito N, Usui J, Yokosawa M, Kondo Y, Inoue S, Okiyama N, Yamagata K.	Anti-PM/Scl Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement.	Intern Med.	60	1101-1107	2021
Kubota N, Saito A, Tanaka R, Nakamura Y, Watanabe R, Fujisawa Y, Ishitsuka Y, Clausen BE, Fujimoto M, Okiyama N.	Langerhans Cells Suppress CD8+ T Cells In Situ during Mucocutaneous Acute Graft-Versus-Host Disease.	J Invest Dermatol.	141	1177-1187	2021
Takagi K, Kawamoto M, Higuchi T, Tochimoto A, Hirose H, Harigai M, Kawaguchi Y.	Characteristics of Japanese patients with systemic sclerosis complicated with calcinosis	Int J Rheum Dis	24	803-808	2021
Yin X, Kim K, Suetsugu H, Bang SY, Wen L, Koido M, Ha E, Liu L, Sakamoto Y, Jo S, Leng RX, Otomo N, Laurynenka V, Kwon YC, Sheng Y, Sugano N, Hwang MY, Li W, Mukai M, Yoon K, Cai M, Ishigaki K, Chung WT, Huang H, Takahashi D, Lee SS, Wang M, Karino K, Shim SC, Zheng X, Miyamura T, Kang YM, Ye D, Nakamura J, Suh CH, Tang Y, Motomura G, Park YB, Ding H, Kuroda T, Choe JY, Li C, Niuro H, Park Y, Shen C, Miyamoto T, Ahn GY, Fei W, Takeuchi T, Shin JM, Li K, Kawaguchi Y, Lee YK, Wang Y, Amano K, Park DJ, Yang W, Tada Y, Yamaji K, Shimizu M, Atsumi T, Suzuki A, Sumida T, Okada Y, Matsuda K, Matsuo K, Kochi Y, Kottyan LC, Weirauch MT, Parameswaran S, Eswar S, Salim H, Chen X, Yamamoto K, Harley JB, Ohmura K, Kim TH, Yang S, Yamamoto T, Kim BJ, Shen N, Ikegawa S, Lee HS, Zhang X, Terao C, Cui Y, Bae SC.	Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus	Ann Rheum Dis	80	632-640	2021
Utsunomiya A, Hasegawa M, Oyama N, Asano Y, Endo H, Fujimoto M, Goto D, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara K, Ihn H	Clinical course of Japanese patients with early systemic sclerosis: a multicenter, prospective, observational study	Mod Rheumatol	31	162-170	2021
Gono T, Masui K, Nishina N, Kawaguchi Y, Kawakami A, Ikeda K, Kirino Y, Sugiyama Y, Tanino Y, Nunokawa T, Kaneko Y, Sato S, Asakawa K, Ukichi T, Kaieda S, Naniwa T, Okano Y, Kuwana M	Risk prediction modeling based on a combination of initial serum biomarkers in myositis-associated interstitial lung disease	Arthritis Rheumatol	73	677-686	2021

Kuwana M, Hasegawa M, Fukue R, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Kawaguchi Y, Sato S, Ihn H, Takehara K	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicenter prospective cohort in Japan	Mod Rheumatol	31(2)	386-393	2021
Shima Y, Watanabe A, Inoue N, Maruyama T, Kunitomo E, Hamano K, Kawanishi T, Takasugi M, Kumanogoh A.	Proximal heat stress up-regulates angiotensin-1 in fingers and reduces the severity of Raynaud's phenomenon in systemic sclerosis: a single-centre pilot study.	Mod Rheumatol	32	351-357	2022
Takizawa A, Kamita M, Kondoh Y, Bando M, Kuwana M, and Inoue Y	Current monitoring and treatment of progressive fibrosing interstitial lung diseases: a survey of physicians in Japan, the United States, and the European Union	Curr. Med. Res. Opin	37(2)	327-339	2021
Azuma A, Chung L, Behera D, Chung M, Kondoh Y, Ogura T, Okamoto M, Swarnakar RN, Zeng X, Zou H, Meng L, Gahlemann M, Alves M, and Kuwana M on behalf of the SENSICIS trial investigators	Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: subgroup analysis of the SENSICIS trial	Respir. Inv	59(2)	252-259	2021
Orlandi M, Landini N, Bruni C, Colagrande S, Pignone AM, Matucci-Cerinic M, and Kuwana M	Infection or autoimmunity? The clinical challenge of interstitial lung disease in systemic sclerosis during COVID 19 pandemic	J. Rheumatol	48(5)	790-792	2021
Ota Y, and Kuwana M	Updates on genetics in systemic sclerosis	Inflamm. Res	41(1)	17	2021
Spiers R, Khanna D, <u>Kuwana M</u> , Furst DE, Frech TM, Hummers L, Stevens W, Matucci-Cerinic M, Baron M, Distler O, Dgetluck N, Bloom BJ, Dinh Q, White B, and Denton CP	A randomized, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale	Clin. Exp. Rheumatol	39 Suppl 131(4)	124-133	2021
Kuwana M, Gil-Vila A, and Selva-O'Callaghan A	Roles of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders	Ther. Adv. Musculoskelet. Dis	13	1759720X 21103245 7	2021
Saketkoo LA, Frech T, Varjú C, Domsic R, Farrell J, Gordon JK, Mihai C, Sandorfi N, Shapiro L, Poole J, Volkman ER, Lammi M, McAnally K, Alexanderson H, Pettersson H, Hant F, Kuwana M, Shah AA, Smith V, Hsu V, Kowal-Bielecka O, Assassi S, Cutolo M, Kayser C, Shanmugam VK, Vonk MC, Fligelstone K, Baldwin N, Connolly K, Ronnow A, Toth B, Suave M, Farrington S, Bernstein EJ, Crofford LJ, Czirájk L, Jensen K, Hinchcliff M, Hudson M, Lammi MR, Mansour J, Morgan ND, Mendoza F, Nikpour M, Pauling J, Riemekasten G, Russell AM, Scholand MB, Seigart E, Rodriguez-Reyna TS, Hummers L, Walker U, and Steen V	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc	Best Prac. Res. Clin. Rheumatol	35(3)	101707	2021
Shirai Y, Fukue R, Kaneko Y, and Kuwana M	Clinical relevance of the serial measurement of Krebs von den Lungen-6 levels in patients with systemic sclerosis-associated interstitial lung disease	Diagnostic s (Basel)	11(11)	2007	2021
Bruni C, Buch MH, De Luca G, Djokovic A, Dumitru RB, Giollo A, Polovina M, Steelandt A, Bratis K, Suliman YA, Milinkovic I, Baritussio A, Hasan G, Xintarakou A, Isomura Y, Markousis-Mavrogenis G, Tofani L, Mavrogeni S, Gargani L, Caforio ALP, Tschoepe C, Ristic A, Klingel K, Plein S, Behr E, Allanore Y, <u>Kuwana M</u> , Denton CP, Furst DE, Khann D, Krieg T, Marcolongo R, Galetti I, Seferovic P, and Matucci-Cerinic M	Primary systemic sclerosis heart involvement: a systematic literature review and preliminary consensus-based WSF/HFA definition.	J. Scleroderma Relet. Disord	7(1)	24-32	2022
Shirai Y, Kawami N, Iwakiri K, and Kuwana M	Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis	J. Scleroderma Relet. Disord	7(1)	57-61	2022
Kuwana M, Allanore Y, Denton CP, Distler JHW, Steen VD, Khanna D, Matucci-Cerinic M, Mayes MD, Volkman ER, Miede C, Gahlemann M, Quaresma Lic M, Alves M, and Distler O	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score	Arthritis Rheumatol	74(3)	518-526	2022

Orlandi M, Landini N, Sambataro G, Nardi C, Tofani L, Bruni C, Bellando-Randone S, Blagojevic J, Melchiorre D, Hughes M, Denton CP, Luppi F, Ruaro B, Della Casa F, De Luca G, Spinicci M, Zammarchi L, Tomassetti S, Caminati A, Cavigli E, Albanesi M, Melchiorre F, Palmucci S, Vegni V, Guiducci S, Moggi-Pignone A, Allanore Y, Bartoloni A, Confalonieri M, Cortese G, Dagna L, de Cobelli F, de Paulis A, Harari S, Khanna D, <u>Kuwana M</u> , Taliani G, Lavorini F, Miele V, Morana G, Pesci A, Vancheri C, Colagrande S, and Matucci-Cerinic M	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19	Rheumatology (Oxford)	10.1093/rheumatology/keab615		Epub ahead of print
Lescoat A, Roofeh D, Kuwana M, Lafyatis R, Allanore Y, and Khanna D	Therapeutic approaches to systemic sclerosis: Recent approvals and future candidate therapies	Clin. Rev. Allergy Immunol	10.1007/s12016-021-08891-0		Epub ahead of print
Yomono K and Kuwana M	Outcomes in patients with systemic sclerosis undergoing early versus delayed intervention with potential disease-modifying therapies	Rheumatology (Oxford)	10.1093/rheumatology/keab931		Epub ahead of print
Isomura Y, Shirai Y, and Kuwana M	Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan	Rheumatology (Oxford)	10.1093/rheumatology/keac136		Epub ahead of print
Satoshi Ebata, Ayumi Yoshizaki, Koji Oba, Kosuke Kashiwabara, Keiko Ueda, Yukari Uemura, Takeyuki Watadani, Takemichi Fukasawa, Shunsuke Miura, Asako Yoshizaki-Ogawa, Yoshihide Asano, Naoko Okiyama, Masanari Kodera, Minoru Hasegawa, Shinichi Sato.	Safety and efficacy of rituximab in systemic sclerosis (DESIREs): a double-blind, investigator-initiated, randomised, placebo-controlled trial	Lancet Rheumatol.	3 (7)	e489-e497	2021
長谷川 稔	全身性強皮症	新薬と臨床	70 (5)	532-535	2021
Utsunomiya A, Chino T, Oyama N, Niwa S, Hasegawa M.	A curcumin-derivative LG283 that inhibits TGF- β /Smad/Snail-dependent mesenchymal transition ameliorates bleomycin-induced skin fibrosis and vascular injury	J Invest Dermatol.	141 (5)	S82	2021
Utsunomiya A, Luong VH, Chino T, Oyama N, Matsushita T, Ishii N, Ogasawara H, Imai T, Hasegawa M.	Anti-fractalkine monoclonal antibody therapy ameliorates murine sclerodermatous chronic graft-versus-host disease	J Invest Dermatol.	141 (10)	S149	2021
Utsunomiya A, Luong VH, Chino T, Oyama N, Matsushita T, Ishii N, Ogasawara H, Imai T, Hasegawa M.	Blockade of CX3CL1-CX3CR1 pathway inhibits mouse sclerodermatous chronic graft-versus-host disease model	The 46h Annual Meeting of the Japanese Society for Investigative Dermatology プログラム		229	2021
Kasamatsu H, Chino T, Hasegawa T, Utsunomiya N, Utsunomiya A, Oyama N, Yamada M, Hasegawa M.	A calpain inhibitor ALLN attenuates bleomycin-induced skin fibrosis in a mice model	The 46h Annual Meeting of the Japanese Society for Investigative Dermatology プログラム		230	2021
長谷川 稔	硬化性苔癬	Clinical Derma.	23 (2)	3-6	2021
長谷川 稔、吉崎 歩、佐藤伸一	強皮症の新規治療	ラジオNIKKEI マルホ皮膚科セミナー	No. 275	4-14	2022
Hatano M, et al	Positive Predictors for Response to Ambrisentan Combination Therapy in Pulmonary Arterial Hypertension	Int Heart J	63	99-105	2022
Tamura Y, Hatano M, et al	Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR).	BMC Pulm med	21		2021

Ikawa T, Hatano M, et al	Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis.	Int J Rheum Dis	24	711-718	2021
波多野 将	結合組織病に伴う肺動脈性肺高血圧症診療の新展開	日本内科学会雑誌	110	2213-2220	2021
波多野 将	肺高血圧症に関わる医療制度について	循環器内科	90	225-230	2021
波多野 将	肺高血圧症診療の現状推進基本計画	循環器内科	90	35-41	2021
Sawamura S, Mijiddorj Myangat T, Kajihara I, Tanaka K, Ide M, Sakamoto R, Otsuka-Maeda S, Kanemaru H, Nishimura Y, Kanazawa-Yamada S, Kashiwada-Nakamura K, Honda N, Makino K, Aoi J, Igata T, Makino T, Masuguchi S, Fukushima S, Ihn H.	Genomic landscape of circulating tumour DNA in metastatic extramammary Paget's disease	Exp Dermatol	31(3)	341-348	2022
Myangat TM, Wada S, Sawamura S, Kajihara I, Kimura T, Kashiwada-Nakamura K, Makino K, Aoi J, Masuguchi S, Fukushima S.	Microsatellite instability analysis using Promega panel in cutaneous squamous cell carcinoma.	J Dermatol	49(2)	e67-e68	2022
Kashiwada-Nakamura K, Myangat TM, Kajihara I, Kanemaru H, Sawamura S, Makino K, Aoi J, Masuguchi S, Fukushima S.	Circulating Janus kinase family DNA levels in psoriasis: elevated JAK2 DNA copy number in cell-free DNA.	J Dermatol	49(3)	e106-e107	2022
Miyashita Y, Yoshida T, Takagi Y, Tsukamoto H, Takashima K, Kouwaki T, Makino K, Fukushima S, Nakamura K, Oshiumi H.	Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination.	NPJ Vaccines	7(1)	16	2022
Tanaka K, Myangat TM, Sawamura S, Otsuka-Maeda S, Sakamoto R, Kanazawa-Yamada S, Kanemaru H, Makino K, Aoi J, Kajihara I, Ihn H.	Genomic mutational profiling of circulating tumour DNA in metastatic angiosarcoma.	J Eur Acad Dermatol Venereol.	35(4)	e293-e295	2021
Otsuka-Maeda S, Mijiddorj MT, Kajihara I, Sakamoto R, Yamada-Kanazawa S, Kanemaru H, Nishimura Y, Sawamura S, Makino K, Aoi J, Makino T, Masuguchi S, Fukushima S, Ihn H.	Overexpression of Janus kinase 2 protein in extramammary Paget's disease.	Jpn J Clin Oncol	51(7)	1176-1178	2021
Mizuhashi S, Kajihara I, Sawamura S, Kanemaru H, Makino K, Aoi J, Makino T, Masuguchi S, Fukushima S, Ihn H.	Skin microbiome in acral melanoma: Corynebacterium is associated with advanced melanoma.	J Dermatol	48(1)	e15-e16	2021
Kaneko A, Kanemaru H, Kajihara I, Mijiddorj T, Miyauchi H, Kuriyama H, Kimura T, Sawamura S, Makino K, Miyashita A, Aoi J, Makino T, Masuguchi S, Fukushima S, Ihn H.	Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.	J Dermatol Sci	102(3)	158-166	2021
Maeda-Otsuka S, Myangat TM, Kajihara I, Sakamoto R, Yamada-Kanazawa S, Sawamura S, Makino K, Masuguchi S, Fukushima S, Ihn H.	Status of microsatellite stability in angiosarcoma: Angiosarcoma is a microsatellite stable tumor.	J Dermatol	48(8)	e368-e369	2021
Kusaba Y, Kajihara I, Sakamoto R, Maeda-Otsuka S, Yamada-Kanazawa S, Sawamura S, Makino K, Aoi J, Masuguchi S, Fukushima S.	Overexpression of tumor endothelial marker 8 protein predicts poor prognosis in angiosarcoma.	J Dermatol	48(10)	e514-e516	2021
Takei I, Sawamura S, Myangat TM, Kajihara I, Kanemaru H, Kashiwada-Nakamura K, Makino K, Aoi J, Masuguchi S, Fukushima S.	Clinical significance of skin colonization of Pseudomonas aeruginosa in cutaneous squamous cell carcinoma.	J Dermatol	48(12)	e581-e582	2021
Kanemaru H, Mizukami Y, Kaneko A, Tagawa H, Kimura T, Kuriyama H, Sawamura S, Kajihara I, Makino K, Miyashita A, Aoi J, Makino T, Masuguchi S, Fukushima S, Ihn H.	A mechanism of cooling hot tumors: Lactate attenuates inflammation in dendritic cells.	iScience	24(9)	103067	2021
Tani S, Kaminaka C, Nishiyama K, Yariyama A, Nakatani Y, Inaba Y, Kunimoto K, Yamamoto Y, Makino K, Makino T, Jinnin M.	yRNA3 up-regulation in cultured dermal fibroblasts and yRNA4 down-regulation in the sera of scleroderma patients.	J Dermatol Sci	102(1)	68-71	2021
Noguchi H, Kubo M, Kashiwada-Nakamura K, Makino K, Aoi J, Fukushima S.	Topical efinaconazole: A sequential combination therapy with oral terbinafine for refractory tinea unguium.	J Dermatol	48(9)	1401-1404	2021
Mizuhashi S, Fukushima S, Ishibashi T, Kuriyama H, Kimura T, Kanemaru H, Kajihara I, Makino K, Miyashita A, Aoi J, Kita K, Ihn H.	Nucleosome assembly protein 1-like 4, a new therapeutic target for proliferation and invasion of melanoma cells.	J Dermatol Sci	102(1)	16-24	2021
Sakamoto R, Kajihara I, Mijiddorj T, Otsuka-Maeda S, Sawamura S, Nishimura Y, Kanemaru H, Kanazawa-Yamada S, Nakamura K, Honda N, Makino K, Aoi J, Igata T, Makino T, Masuguchi S, Fukushima S, Morinaga J, Komohara Y, Ihn H.	Existence of Staphylococcus aureus correlates with the progression of extramammary Paget's disease: potential involvement of interleukin-17 and M2-like macrophage polarization.	Eur J Dermatol	31(1)	48-54	2021
Baral H, Uchiyama A, Yokoyama Y, Sekiguchi A, Yamazaki S, Amalia SN, Inoue Y, Ogino S, Torii R, Hosoi M, Matsuzaki T, Motegi SI.	Antifibrotic effects and mechanisms of mesenchymal stem cell-derived exosomes in a systemic sclerosis mouse model: Possible contribution of miR-196b-5p.	Journal of Dermatological Science	104(1)	39-47	2021

Baral H, Sekiguchi A, Uchiyama A, Nisaa Amalia S, Yamazaki S, Inoue Y, Yokoyama Y, Ogino S, Torii R, Hosoi M, Akai R, Iwawaki T, Ishikawa O, Motegi SI.	Inhibition of skin fibrosis in systemic sclerosis by botulinum toxin B via the suppression of oxidative stress.	Journal of Dermatology	48(7)	:1052-1061.	2021
Nishio M, Endo Y, Kosaka K, Saito S, Uehara A, Yamazaki S, Sekiguchi A, Ishikawa O, Motegi SI.	Anti-aminoacyl-tRNA synthetases antibody	Journal of Dermatology	48(2)	:e110-e111.	2021
茂木精一郎、清水晶	強皮症のレイノー現象や手指潰瘍に対する治療に関する最新の話題 ボツリヌス毒素局所注入療法が有用であり、適応疾患の拡大が期待される	日本医事新報	5092	52-53	2021
茂木精一郎	最近のトピックス2021 Clinical Dermatology 2021】皮膚疾患治療のポイント 強皮症に伴うRaynaud現象・手指潰瘍に対するボツリヌス毒素局所注入療法	臨床皮膚科	75(5)	Page115-119	2021
Ishikawa M, Yamamoto T.	Antifibrotic effects of C-C chemokine re	Exp Dermatol	30	179-184	2021
Ito T, Mori T, Miura T, Yamamoto T.	Pediatric-onset solitary morphea profunda	Int J Dermatol	60	e116-e117	2021
山本俊幸	小児膠原病のnatural course	皮膚病診療	43	220-227	2021
山本俊幸	小児の膠原病の皮疹	日本皮膚免疫アレルギー学会雑誌	3	381-390	2021

令和2年度 研究成果の刊行に関する一覧表

【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
茂木精一郎	S5c指尖潰瘍治療アップデート	宮地良樹, 常深祐一郎, 鶴田大輔	Whats new? in 皮膚科学 2020-2021	メディカルレビュー社	日本	2020	pp. 168-169

【雑誌】

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Fujimoto M, Asai J, Asano Y, Ishii T, Iwata Y, Kawakami T, Koderu M, Abe M, Amano M, Ikegami R, Isei T, Isogai Z, Ito T, Inoue Y, Irisawa R, Ohtsuka M, Omoto Y, Kato H, Kadono T, Kaneko S, Kanoh H, Kawaguchi M, Kukino R, Kono T, Koga M, Sakai K, Sakurai E, Sarayama Y, Shintani Y, Tanioka M, Tanizaki H, Tsujita J, Doi N, Nakanishi T, Hashimoto A, Hasegawa M, Hayashi M, Hirosaki K, Fujita H, Fujiwara H, Maekawa T, Matsuo K, Madokoro N, Motegi SI, Yatsushiro H, Yamasaki O, Yoshino Y, Pavoux AJL, Tachibana T, Ihn H: Japanese Dermatological Association Guidelines.	Wound, pressure ulcer and burn guidelines - 4: Guidelines for the management of connective tissue disease/vasculitis-associated skin ulcers.	J Dermatol.	47(10)	1071-1109	2020
Utsunomiya A, Hasegawa M, Oyama N, Asano Y, Endo H, Fujimoto M, Goto D, Ishikawa O, Kawaguchi Y, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara K, Ihn H.	Clinical course of Japanese patients with early systemic sclerosis: A multicenter, prospective, observational study.	Mod Rheumatol	31 (1)	162-170	2021
Chunyan Zhao, Takashi Matsushita, Vinh Thi Ha Nguyen, Momoko Tennichi, Manabu Fujimoto, Kazuhiko Takehara, Yasuhiro Hamaguchi	CD22 and CD72 contribute to the development of scleroderma in a murine model	J Dermatol Sci	97(1)	66-76	2020
Toyama S, Yamashita T, Saigusa R, Miura S, Nakamura K, Hirabayashi M, Miyagawa T, Fukui Y, Omatsu J, Yoshizaki A, Sato S, Asano Y.	Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease.	J Dermatol.	47(9)	1027-1032	2020
Ebata S, Yoshizaki A, Fukasawa T, Asano Y, Oba K, Sato S.	Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease.	J Dermatol.	47(7)	796-800	2020
Aozasa N, Hatano M, Saigusa R, Nakamura K, Takahashi T, Toyama T, Sumida H, Tamaki Z, Maki H, Minatsuki S, Komuro I, Sato S, Asano Y.	Clinical significance of endothelial vasodilatory function evaluated by EndoPAT in patients with systemic sclerosis.	J Dermatol.	47(6)	609-614	2020
Miyagawa T, Taniguchi T, Saigusa R, Fukayama M, Takahashi T, Yamashita T, Hirabayashi M, Miura S, Nakamura K, Yoshizaki A, Sato S, Asano Y.	Fli1 deficiency induces endothelial adiponin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis.	Rheumatology (Oxford)	59(8)	2005-2015	2020
Yamamoto T, Ito T, Asano Y, Sato S, Motegi SI, Ishikawa O, Matsushita T, Takehara K, Makino T, Okiyama N, Fujimoto M, Jinnin M, Ihn H.	Characteristics of Japanese patients with eosinophilic fasciitis: A brief multicenter study.	J Dermatol.	47(12)	1391-1394	2020
Maki H, Kubota K, Hatano M, Minatsuki S, Amiya E, Yoshizaki A, Asano Y, Morita H, Sato S, Komuro I.	Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.	Int Heart J.	61(2)	413-418	2020
Fukui Y, Miyagawa T, Toyama S, Omatsu J, Hirabayashi M, Nakamura K, Yoshizaki A, Sato S, Asano Y.	Serum delta-like 4 levels: A possible association with interstitial lung disease in systemic sclerosis.	J Dermatol.	47(4)	e136-e137	2020
Asano Y, Sato S.	Localized scleroderma-like lesions induced by the Köbner phenomenon in a patient with systemic sclerosis positive for anticentromere antibody.	Eur J Dermatol.	30(4)	431-432	2020
Aozasa N, Miyazaki M, Hayakawa J, Tamaki T, Hamaguchi Y, Sato S, Asano Y.	Case of systemic sclerosis with multiple primary malignancies in whom anti-RNA polymerase III antibody was detected by immunoprecipitation.	J Dermatol.	47(7)	e269-e270	2020
Nakamura K, Sato S, Asano Y.	Overlapping systemic sclerosis and sarcoidosis with mutually exclusive disease activities: a case report and analysis of previous studies.	Eur J Dermatol.	30(1)	50-52	2020
Toyama S, Sato S, Asano Y.	Localized scleroderma histologically characterized by liquefaction degeneration and upper dermis fibrosis: a possible association with chemotherapy.	Clin Exp Dermatol.	45(5)	632-634	2020
Nakamura K, Ichimura Y, Tamaki Z, Yoshizaki A, Sato S, Asano Y.	Acute exacerbation of interstitial lung disease with onset of myositis in systemic sclerosis patients: a report of two cases.	Scand J Rheumatol.	49(3)	247-248	2020
Asano Y.	The Pathogenesis of Systemic Sclerosis: An Understanding Based on a Common Pathologic Cascade across Multiple Organs and Additional Organ-Specific Pathologies.	J Clin Med.	9	E2687	2020

Asano Y, Varga J.	Rationally-based therapeutic disease modification in systemic sclerosis: Novel strategies.	Semin Cell Dev Biol.	101	146-160	2020
Omatsu J, Saigusa R, Miyagawa T, Fukui Y, Toyama S, Awaji K, Ikawa T, Norimatsu Y, Yoshizaki A, Sato S, Asano Y.	Serum S100A12 levels: possible association with skin sclerosis and interstitial lung disease in systemic sclerosis.	Exp Dermatol.	30(3)	409-415	2021
Ikawa T, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis.	Int J Rheum Dis.	24(2)	260-267	2021
Kotani H, Yoshizaki A, Matsuda KM, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum calponin 3 levels in patients with systemic sclerosis: possible association with skin sclerosis and arthralgia.	J Clin Med.	10(2)	280	2021
Kuzumi A, Yoshizaki A, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum TARC levels in patients with systemic sclerosis: clinical association with interstitial lung disease.	J Clin Med.	10(4)	660	2021
Matsuda KM, Yoshizaki A, Kotani H, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Clinical significance of anti-U1 ribonucleoprotein antibody in anti-topoisomerase I antibody-positive systemic sclerosis patients: a retrospective observational study.	Arch Clin Biomed Res.	5(1)	76-84	2021
Matsuda KM, Yoshizaki A, Kotani H, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S.	Serum heat shock protein 27 levels in patients with systemic sclerosis: a possible biomarker of skin sclerosis.	J Eur Acad Dermatol Venereol.	35(2)	e157-e159	2021
Yuki F, Nakamura K, Hirabayashi M, Miyagawa T, Toyama S, Omatsu J, Awaji K, Ikawa T, Norimatsu Y, Yoshizaki A, Sato S, Asano Y.	Serum vasohibin-1 levels: a potential marker of dermal and pulmonary fibrosis in systemic sclerosis.	Exp Dermatol.	doi: 10.1111/exd.14321.	Online ahead of print.	2021
Awaji K, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Norimatsu Y, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	A potential contribution of decreased serum galectin-10 levels to systemic inflammation and pulmonary vascular involvement in systemic sclerosis.	Exp Dermatol.	doi: 10.1111/exd.14320.	Online ahead of print.	2021
Ikawa T, Miyagawa T, Fukui Y, Minatsuki S, Maki H, Inaba T, Hatano M, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis.	Int J Rheum Dis.	24(5)	711-718	2021
Saigusa R, Toyama T, Ichimura Y, Taniguchi T, Yoshizaki A, Sato S, Asano Y.	A case of systemic sclerosis complicated with portal hypertension.	J Clin Rheumatol.	doi: 10.1097/RHU.0000000000001633.	Online ahead of print.	2020
Norimatsu Y, Miyagawa T, Fukui Y, Omatsu J, Toyama S, Awaji K, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y.	Serum levels of tissue factor pathway inhibitor: potential association with Raynaud's phenomenon and telangiectasia in patients with systemic sclerosis.	J Dermatol.	doi: 10.1111/1346-8138.15893.	Online ahead of print.	2021
Ebata S, Yoshizaki A, Oba K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Asano Y, Okiyama N, Kodera M, Hasegawa M, Sato S.	Safety and efficacy of rituximab in systemic sclerosis: a double-blind, parallel-group comparison, investigators initiated clinical trial (DESIREs).	Lancet Rheumatol.	in press		2021
Ly NTM, Ueda-Hayakawa I, Nguyen CTH, Huynh NM, Kishimoto I, Fujimoto M, Okamoto H.	Imbalance toward TFH 1 cells playing a role in aberrant B cell differentiation in systemic sclerosis.	Rheumatology	60(3)	1553-1562	2021
Nomura Y, Ueda-Hayakawa I, Yamazaki F, Ozaki Y, Hamaguchi Y, Takehara K, Okamoto H	A case of anti-RuvBL1/2 antibody-positive systemic sclerosis overlapping with myositis	Eur J Dermatol.	30(1)	52-53	2020
Saito A, Ichimura Y, Kubota N, Tanaka R, Nakamura Y, Fujisawa Y, Watanabe R, Ishitsuka Y, Fujimoto M, Okiyama N.	Interferon-g-stimulated apoptotic keratinocytes promote sclerodermatous changes in chronic graft-versus-host disease.	J Invest Dermatol.	141(6)	1473-1481	2020
Yamashita K, Kawasaki A, Matsushita T, Furukawa H, Kondo Y, Okiyama N, Nagaoka S, Shimada K, Sugii S, Katayama M, Hirohata S, Okamoto A, Chiba N, Suematsu E, Setoguchi K, Migita K, Sumida T, Tohma S, Hamaguchi Y, Hasegawa M, Sato S, Kawaguchi Y, Takehara K, Tsuchiya N.	Association of functional (GA)n microsatellite polymorphism in the FLI1 gene with susceptibility to human systemic sclerosis.	Rheumatology (Oxford)	59(11)	3553-3562	2020
Shimizu T, Saito C, Watanabe M, Ishii R, Kawamura T, Nagai K, Fujita A, Kaneko S, Kai H, Morito N, Usui J, Yokosawa M, Kondo Y, Inoue S, Okiyama N, Yamagata K.	Anti-PM/Scl Antibody-positive Systemic Sclerosis Complicated by Multiple Organ Involvement.	Intern Med.	60(7)	1101-1107	2020
Takagi K, Kawamoto M, Higuchi T, Tochimoto A, Harigai M, Kawaguchi Y.	Single nucleotide polymorphisms of the HIF1A gene are associated with susceptibility to pulmonary arterial hypertension in systemic sclerosis and contribute to SSc-PAH disease severity.	Int J Rheum Dis	23	674-680	2020
Jinnin M, Ohta A, Ishihara S, Amano H, Atsumi T, Fujimoto M, Kanda T, Kawaguchi Y, Kawakami A, Mimori T, Mimura T, Muro Y, Sano H, Shimizu J, Takeuchi T, Tanaka Y, Yamamoto K, Sumida T, Kohsaka H	First external validation of sensitivity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort.	Ann Rheum Dis	79	387-392	2020

Miyamae T, Hanaya A, Kawamoto M, Tani Y, Kawaguchi Y, Yamanaka H	Diagnostic rate of autoinflammatory diseases evaluated by fever patterns in pediatric- and adult-onset patients	J Clin Rheumatol	26	60-62	2020
Tani Y, Kishi T, Miyamae T, Kawamoto M, Kawaguchi Y, Taniguchi A, Yamanaka H	The evaluation of gene polymorphisms associated with autoinflammatory syndrome in patients with palindromic rheumatism complicated by intermittent hydrarthrosis.	Clin Rheumatol	39	841-845	2020
Hirahara S, Katsumata Y, Kawasumi H, Kawaguchi Y, Harigai M	Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity	Lupus	29	686-696	2020
Matucci-Cerinic M, Bruni C, Allanore Y, Clementi M, Dagna L, Damjanov N, De Paulis A, Denton CP, Distler O, Fox D, Furst DE, Khanna D, Krieg T, Kuwana M, Lee EB, Li, Pillai S, Wang Y, Zeng X, and Taliani G	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management	Ann. Rheum. Dis	79(6)	724-726	2020
380. Nagaraja V, Matucci-Cerinic M, Furst DE, Kuwana M, Allanore Y, Denton CP, Raghu G, McLaughlin V, Rao PS, Seibold JR, Pauling J, Whitfield ML, and Khanna D	Current and future outlook on disease modification and defining low disease activity in systemic sclerosis	Arthritis Rheumatol	72(7)	1049-1058	2020
Yamasaki Y, and *Kuwana M	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease	Expert Rev. Clin. Immunol	16(6)	547-559	2020
383. Enoe Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, and Brown KK	Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype	Chest	158(2)	646-659	2020
Ota Y and *Kuwana M	Endothelial cells and endothelial progenitor cells in pathogenesis of systemic sclerosis	Eur. J. Rheumatol	7(suppl 3)	S139-146	2020
Hamaguchi Y, Kuwana M, and Takehara K	Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies	Clin. Rheumatol	39(11)	3489-3497	2020
388. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar J, Spotswood H, Wagner B, Siegel J, Jhreis A, and Denton CP	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.	Lancet Respir. Med	8(10)	963-974	2020
*Kuwana M, Ogura T, Makino S, Homma S, Kondoh Y, Saito A, Ugai H, Gahlemann M, Takehara K, and Azuma A	Nintedanib in patients with systemic sclerosis associated interstitial lung disease: A Japanese population analysis of the SENSICIS trial	Mod. Rheumatol	31(1)	141-150	2021
Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, Denton CP, Distler JHW, Hoffmann-Vold AM, Khanna D, Mayes MD, Raghu G, Vonk MC, Gahlemann M, Clerisme-Beatty E, Girard M, Stowasser S, Zoz D, and Maher TM on behalf of the SENSICIS trial investigators	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: subgroup analysis of the SENSICIS trial	Lancet Respir. Med	9(1)	96-106	2021
Nawata T, Shirai Y, Suzuki M, and *Kuwana M	Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-interstitial lung disease.	Rheumatology (Oxford)	60(1)	250-255	2021
Tamura Y, Kumamaru H, Abe K, Satoh T, Miyata H, Ogawa A, Tanabe N, Hatano M, Yao A, Tsuzino I, Fukuda K, Kimura H, Kuwana M, Matsubara H, Tatsumi K, and the Japan PH Registry (JAPHR) Network	Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: A subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR)	BMC Pulm. Med	21(1)	28	2021
*Kuwana M, Hasegawa M, Fukue R, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Kawaguchi Y, Sato S, Ihn H, and Takehara K	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: results from a multicentre prospective cohort in Japan.	Mod. Rheumatol	31(2)	386-393	2021
Azuma A, Chung L, Behera D, Chung M, Kondoh Y, Ogura T, Okamoto M, Swarnakar RN, Zeng X, Zou H, Meng L, Gahlemann M, Alves M, and Kuwana M on behalf of the SENSICIS trial investigators	Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: subgroup analysis of the SENSICIS trial.	Respir. Invest	59(2)	252-259	2021
Orlandi M, Landini N, Bruni C, Colagrande S, Pignone AM, Matucci-Cerinic M, and Kuwana M	Infection or autoimmunity? The clinical challenge of interstitial lung disease in systemic sclerosis during COVID 19 pandemic	J. Rheumatol	48(5)	790-792	2021
Utsunomiya A, Hasegawa M, Oyama N, Asano Y, Endo H, Fujimoto M, Goto D, Ishikawa O, Kawaguchi S, Kuwana M, Ogawa F, Takahashi H, Tanaka S, Sato S, Takehara T, Ihn H.	Clinical course and treatment outcome of Japanese patients with early progressive systemic sclerosis: a multicenter, prospective, observational study	Mod Rheumatol	31(1)	162-170	2021
Kuwana M, Hasegawa M, Fukue R, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Kawaguchi Y, Sato S, Ihn H, Takehara K.	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan	Mod Rheumatol	31(2)	386-393	2021
Tani S, Kaminaka C, Nishiyama K, Yariyama A, Nakatani Y, Inaba Y, Kunimoto K, Yamamoto Y, Makino K, Makino T, Jinnin M.	yRNA3 up-regulation in cultured dermal fibroblasts and yRNA4 down-regulation in the sera of scleroderma patients.	J Dermatol Sci.	102(1)	68-71	2021

Tabata K, Jinnin M, Furukawa K, Tani S, Okuhira H, Mikita N, Fujii T.	Finger sweating levels evaluated by video capillaroscopy system are increased in patients with systemic sclerosis compared to pre-clinical stage patients.	Drug Discov Ther.	14(6)	325-329	2021
Shimada S, Makino K, Jinnin M, Sawamura S, Kawano Y, Ide M, Kajihara I, Makino T, Fukushima S, Ihn H.	CXCL17-mediated downregulation of type I collagen via MMP1 and miR-29 in skin fibroblasts possibly contributes to the fibrosis in systemic sclerosis.	J Dermatol Sci.	100(3)	183-191	2020
Utsunomiya N, Utsunomiya A, Chino T, Hasegawa M, Oyama N.	Gene silencing of extracellular matrix protein 1 (ECM1) results in phenotypic alterations of dermal fibroblasts reminiscent of clinical features of lichen sclerosus.	J Dermatol Sci.	100(2)	99-109	2020
Kuwana M, Hasegawa M, Fukue R, Shirai Y, Ishikawa O, Endo H, Ogawa F, Goto D, Kawaguchi Y, Sato S, Ihn H, Takehara K.	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan.	Mod Rheumatol.	31(2)	386-393	2021
Utsunomiya A, Oyama N, Hasegawa M.	Potential Biomarkers in Systemic Sclerosis: A Literature Review and Update.	J Clin Med.	9(11)	3388	2020
Kawabata K, Makino T, Makino K, Kajihara I, Fukushima S, Ihn H.	IL-16 expression is increased in the skin and sera of patients with systemic sclerosis.	Rheumatology (Oxford).	59(3)	519-523	2020
Oshikawa Y, Makino T, Nakayama M, Sawamura S, Makino K, Kajihara I, Aoi J, Masuguchi S, Fukushima S, Ihn H.	Increased CD27 expression in the skins and sera of patients with systemic sclerosis.	Intractable Rare Dis Res.	9(2)	99-103	2020
Sekiguchi A, Inoue Y, Yamazaki S, Uchiyama A, Ishikawa O, Kuribayashi S, Uraoka T, Hara K, Yamaguchi K, Maeno T, Uchida M, Koyama H, Motegi S.	Prevalence and clinical characteristics of earlobe crease in systemic sclerosis: Possible association with vascular dysfunction.	Journal of Dermatology	47(8)	870-875	2020
Yamamoto T, et al.	Characteristics of Japanese patients with eosinophilic fasciitis: a multicenter brief study.	J Dermatol	47	1391-1394	2020
Watanabe Y, Yamamoto M, Yamamoto T.	A case of eosinophilic fasciitis and generalized morphea overlap.	Dermatol Online J	26	13030	2020
長谷川 稔	【臓器線維症を科学する-病態解明と治療法開発への展望】 臓器特異性と共通性、全身性強皮症の皮膚線維化の機序と治療標的	週刊医学のあゆみ	275(10)	1143-1148	2020
尾山徳孝、宇都宮夏子、長谷川 稔	白斑や抗甲状腺抗体などの自己免疫異常を伴った外陰部硬化性苔癬	皮膚病診療	42(4)	310-331	2020
長谷川 稔	診療の秘訣 膠原病の診断 “爪のまわりをみる”	Modern Physician	40(3)	290	2020
波多野将	心筋障害の評価とその管理	リウマチ科	第63巻第5号	515-523	2020
牧野貴充	【冬の皮膚病】治療 全身性強皮症の皮膚潰瘍に対するボセンタン治療の効果と実際	皮膚病診療	42(12)	1046-1052	2020
茂木 精一郎、石川 治	難治性指尖潰瘍の評価とその管理	リウマチ科	63	493-499	2020
茂木 精一郎	全身性強皮症に伴う末梢循環障害に対するボツリヌス毒素局所注入療法	月刊BIO INDUSTRY	37	95-103	2020